Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2026-03-05 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
北京市康达律师事务所关于赛隆药业集团股份有限公司2026年第三次临时股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures, attendance, and voting results of the 2026 third extraordinary shareholders' meeting of a company. It details the convening, attendance, voting procedures, and results of the shareholders' meeting, confirming compliance with relevant laws and company articles. This is not the actual shareholder meeting materials or minutes but a legal opinion on the meeting's conduct and voting results. Such documents are typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as they officially confirm and announce the voting outcomes and procedural compliance of a shareholders' meeting. The document length is under 5,000 characters, but it contains substantive legal opinion and detailed voting results, not just a brief announcement or a report publication notice. Therefore, the best fit is DVA.
2026-03-05 Chinese
关于2026年第三次临时股东会增加临时提案暨股东会补充通知的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the company's 2026 third extraordinary general meeting of shareholders (临时股东会). It includes information about the meeting date, location, voting procedures (including network voting), agenda items, and proxy forms. The content focuses on notifying shareholders about the meeting and the proposals to be voted on, including remuneration policies, appointment of auditors, and transfer of subsidiary shares. There are no financial statements or detailed financial performance data presented. The document is not a report itself but an official notice and supplementary information about the shareholder meeting and its agenda. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is primarily a notice about the meeting and proposals for shareholder voting, and includes proxy forms and voting instructions, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length is 4672 characters, which is sufficient for a detailed proxy statement. Hence, the classification is PSI with high confidence.
2026-02-13 Chinese
赛隆药业集团股份有限公司拟转让股权涉及的湖南赛隆生物制药有限公司股东全部权益市场价值资产评估报告
Regulatory Filings
2026-02-13 Chinese
湖南赛隆生物制药有限公司2025年1-9月审计报告
Regulatory Filings
2026-02-13 Chinese
湖南赛隆生物制药有限公司2024年度审计报告
Regulatory Filings
2026-02-13 Chinese
第四届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 23rd meeting of the 4th Board of Directors of the company. It details the meeting's convening, attendance, and voting results on a specific agenda item related to the transfer of a subsidiary's equity. There is no financial data, no annual or quarterly report content, and no mention of audit or earnings results. The document focuses on board meeting decisions and governance matters. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear content and format.
2026-02-13 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.